Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices 45229 

Frequency of response: Applicants may 

submit applications for published 

receipt dates. If awarded, annual 

progress is reported and trainees may be 

appointed or reappointed. Affected 

Public: Individuals or Households; 

Business or other for-profit; Not-forprofit institutions; Federal Government; 

and State, Local or Tribal Government. 

Type of Respondents: Adult scientific 

trainees and professionals. The annual 

reporting burden is as follows: 

Estimated Number of Respondents: 

34,454; Estimated Number of Responses 

per Respondent: 1; Average Burden 

Hours per Response: 4.1; and Estimated 

Total Annual Burden Hours Requested: 

142,301. The annualized cost to 

respondents is estimated at: $4,980,535. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time should be sent via e-mail to 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact Ms. 

Mikia Currie, Project Clearance Branch, 

Office of Policy for Extramural Research 

Administration, NIH, Rockledge 1 

Building, Suite 350, 6705 Rockledge 

Drive, Bethesda, MD 20892–7974, or 

call non-toll-free number (301) 435–

0941, or e-mail your request, including 

your address to: curriem@od.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

Dated: July 24, 2008. 

Pam Gilden, 

Division of Grants Policy, Office of Policy 

for Extramural Research Administration, 

Office of Extramural Research, National 

Institutes of Health. 

[FR Doc. E8–17727 Filed 8–1–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Antibodies and Antisera Recognizing 

Members of the ArfGap Family of 

Proteins 

Description of Technology 

The technology involves antibodies 

and antisera that recognize members of 

the ArfGap protein family, including the 

following proteins: 

• ACAP1, which is related to ASAP1, 

a putative oncogene that regulates 

cancer cell invasion into normal tissues. 

ACAP1 regulates integrins, which are 

critical for cell movement associated 

with cancer cell invasion and is a target 

of the oncogene Akt. 

• ACAP2, which is related to ASAP1, 

a putative oncogene that regulates 

cancer cell invasion into normal tissues. 

• AGAP2 (also known as PIKE–A), 

ASAP1 (also called AMAP1 and DDEFl), 

and ASAP3 all exhibit elevated 

expression levels in cancer cells 

compared to non-transformed cells and 

as putative oncogenes have been 

implicated as regulators of cancer cell 

invasion into normal tissues and 

contributors to brain, eye and breast, 

and liver cancers, respectively. 

• ARAP1 (also called Centaurin Delta 

2), which has been implicated as a 

regulator of epidermal growth factor 

receptor, which plays important roles in 

several malignancies. 

• ARAP2 (also called Centaurin Delta 

1), GIT1 and GIT2; all three of which 

have been implicated as regulators of 

cell migration required for cancer cell 

invasion into normal tissues and 

metastasis. 

• ARAP3, a target of the Src 

oncogene, has been implicated as a 

regulator of cell movement and 

signaling. 

• ArfGAP1, which is critical to cell 

function, including protein trafficking. 

• ASAP2 (also known as PAG3 or as 

Pap in the 1999 Molecular and Cellular 

Biology publication), is highly related to 

ASAP1, which has been implicated as a 

regulator of cancer cell invasion into 

normal tissues. 

The table below summarizes the 

antibodies and antisera available against 

different ArfGap proteins. Each material 

has been raised or generated to the 

peptide sequence listed. 

ANTIBODIES AND ANTISERA RECOGNIZING ARFGAP PROTEINS

ArfGap member Antibody/serum ID (Alt. 

Name) 

Antibody 

source Peptide sequence (ID) HHS Ref. No. 

ACAP1 .......... 1241 (Arf6-specific GAP) ....... Rabbit ........... RPRGQPPVPPKPSIR(556) .................................................... E–244–2008/0 

ACAP2 .......... 1288 ........................................ Rabbit ........... REKGDESEKLDKKSS(365) .................................................... E–242–2008/0 

AGAP2 .......... 4569, 4571 ............................. Rabbit ........... ERVDDPELQDSI and PLSREPPPSPMVKKQ .......................

(483) .....................................................................................

E–222–2008/0 

ARAP1 .......... 1153 ........................................ Rabbit ........... SLIPLRGSENEMRRSV ........................................................... E–220–2008/0 


pwalker on PROD1PC71 with NOTICES
45230 Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices 

ANTIBODIES AND ANTISERA RECOGNIZING ARFGAP PROTEINS—Continued 

ArfGap member Antibody/serum ID (Alt. 

Name) 

Antibody 

source Peptide sequence (ID) HHS Ref. No. 

ARAP2 .......... 1185, 1187 ............................. Rabbit ........... RSRTLPKELQDEQILK ............................................................

(1689) and ANVHKTKKNDDPSKDY ...................................

E–220–2008/1 

ARAP3 .......... 862, 863, 864, 865 (CENTD3/ 

DRAG1).

Rabbit ........... DKDPPFPKGVIPLTAIE and EPVYEEPVYEEVGAFPE ......... E–220–2008/2 

ArfGAP1 ....... 870 .......................................... Rabbit ........... EWSLESSPAQNWTPPQP .....................................................

(123) .....................................................................................

E–243–2008/0 

ASAP1 .......... 642, 645, 551, 553 ................. Rabbit ........... VELAPKPQVGELPPKPG (962), DQDRTALQKVKKSVAC, 

and murine protein residues 325–725; 440–724.

E–221–2008/0 

ASAP1a ........ 574 .......................................... Rabbit ........... LSKKPPPPPPGHKRTL ..........................................................

(837) .....................................................................................

E–221–2008/0 

ASAP1 .......... ................................................. Mouse .......... VELAPKPQVGELPPKPG .......................................................

(962) .....................................................................................

E–252–2008/0 

ASAP2 .......... 1267, 4574, 4575, 578 ........... Rabbit ........... DEKLQPSPNRREDRP(706) and human protein fragment of 

the PH, Arf GAP and Ankyrin repeat domains.

E–221–2008/1 

ASAP3 .......... Anti-ASAP3 (DDEFL1/UPLC1/ 

ACAP4).

Rabbit ........... WVISTEPGSDSEEDEEKR ..................................................... E–221–2008/2 

GIT1 .............. ................................................. Rabbit ........... LRQPPGPVPTPPLPSER and RKTVPPEPGAPVDF ............. E–245–2008/0 

GIT2 .............. ................................................. Rabbit ........... RSSEVCADCSGPDPS and KVNNNLSDELRIMQKK ............. E–245–2008/1 

Applications 

• Immunoblotting and other 

procedures to identify the ArfGap 

proteins in cells and tissues; 

• Identifying tumors, such as those 

found in brain, breast, eye and liver 

cancers, based on protein expression 

levels; 

• Examining the invasive behavior of 

tumor cells. 

Development Status 

The antibodies and antisera have been 

raised or generated to the particular 

peptide sequence given in the table 

above. These are available as Research 

Tools. 

Inventors 

Paul A. Randazzo et al. (NCI). 

Relevant Publications 

These antibodies and antisera are 

further described in the following 

research articles: 

1. Andreev J, Simon JP, Sabatini DD, 

Kam J, Plowman G, Randazzo PA, 

Schlessinger J. Identification of a new 

Pyk2 target protein with Arf-GAP 

activity. Mol Cell Biol. 1999 

Mar;19(3):2338–2350. 

2. Bharti S, Inoue H, Bharti K, Hirsch 

DS, Nie Z, Yoon HY, Artym V, 

Yamada KM, Mueller SC, Barr VA, 

Randazzo PA. Src-dependent 

phosphorylation of ASAP1 regulates 

podosomes. Mol Cell Biol. 2007 

Dec;27(23):8271–8283. 

3. Dai J, Li J, Bos E, Porcionatto M, 

Premont RT, Bourgoin S, Peters PJ, 

Hsu VW. ACAP1 promotes endocytic 

recycling by recognizing recycling 

sorting signals. Dev Cell. 2004 

Nov;7(5):771–776. 

4. Ha VL et al. ASAP3 is a focal 

adhesion-associated Arf GAP that 

functions in cell migration and 

invasion. J Biol Chem. 2008 May 

30;283(22):14915–14926. 

5. I ST, Nie Z, Stewart A, Najdovska M, 

Hall NE, He H, Randazzo PA, Lock P. 

ARAP3 is transiently tyrosine 

phosphorylated in cells attaching to 

fibronectin and inhibits cell spreading 

in a RhoGAP-dependent manner. J 

Cell Sci. 2004 Dec 1;117(Pt 25):6071–

6084. 

6. Inoue H and Randazzo PA. Arf GAPs 

and their interacting proteins. Traffic 

2007 Nov;8(11):1465–1475. 

7. Li J, Ballif BA, Powelka AM, Dai J, 

Gygi SP, Hsu VW. Phosphorylation of 

ACAP1 by Akt regulates the 

stimulation-dependent recycling of 

integrin beta1 to control cell 

migration. Dev Cell. 2005 

Nov;9(5):663–673. 

8. Miura K, Jacques KM, Stauffer S, 

Kubosaki A, Zhu K, Hirsch DS, Resau 

J, Zheng Y, Randazzo PA. ARAP1: a 

point of convergence for Arf and Rho 

signaling. Mol Cell 2002 Jan;9(1):109–

119. 

9. Nie Z, Fei J, Premont RT, Randazzo 

PA. The Arf GAPs AGAP1 and 

AGAP2 distinguish between the 

adaptor protein complexes AP–1 and 

AP–3. J Cell Sci. 2005 Aug 1;118(Pt 

15):3555–3566. 

10. Randazzo PA, Andrade J, Miura K, 

Brown MT, Long YQ, Stauffer S, 

Roller P, Cooper JA. The Arf GTPaseactivating protein ASAP1 regulates 

the actin cytoskeleton. Proc Natl Acad 

Sci USA. 2000 Apr 11;97(8):4011–

4016. 

11. Liu W, Duden R, Phair RD, 

Lippincott-Schwartz J. ArfGAP1 

dynamics and its role in COPI coat 

assembly on Golgi membranes of 

living cells. J. Cell Biol. 2005 Mar 

28;168(7):1053–1063. 

12. Yoon MY, Miura K, Cuthbert EJ, 

Davis KK, Ahvazi B, Casanova JE, 

Randazzo PA. ARAP2 effects on the 

actin cytoskeleton are dependent on 

Arf6-specific GTPase-activatingprotein activity and binding to RhoA–

GTP. J Cell Sci. 2006 Nov 15;119(Pt 

22):4650–4666. 

Patent Status 

Patent protection is not being pursued 

for this technology. 

• HHS Reference No. E–220–2008/ 

0—Research Tool. 

• HHS Reference No. E–220–2008/ 

1—Research Tool. 

• HHS Reference No. E–220–2008/ 

2—Research Tool. 

• HHS Reference No. E–221–2008/ 

0—Research Tool. 

• HHS Reference No. E–221–2008/ 

1—Research Tool. 

• HHS Reference No. E–221–2008/ 

2—Research Tool. 

• HHS Reference No. E–222–2008/ 

0—Research Tool. 

• HHS Reference No. E–242–2008/ 

0—Research Tool. 

• HHS Reference No. E–243–2008/ 

0—Research Tool. 

• HHS Reference No. E–244–2008/ 

0—Research Tool. 

• HHS Reference No. E–245–2008/ 

0—Research Tool. 

• HHS Reference No. E–245–2008/ 

1—Research Tool. 

• HHS Reference No. E–252–2008/ 

0—Research Tool. 

Licensing Status 

Available for non-exclusive biological 

materials licensing only. 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices 45231 

Licensing Contact 

Surekha Vathyam, Ph.D.; 301–435–

4076; vathyams@mail.nih.gov. 

Dated: July 28, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–17812 Filed 8–1–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Development of Human 

Therapeutics for the Treatment of 

Depression 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

11/137,114 entitled ‘‘Scopolamine For 

The Treatment Of Depression And 

Anxiety’’ [HHS Ref. E–175–2004/0–US–

01], PCT Application PCT/US2006/ 

019335 [HHS Ref. E–175–2004/0–PCT–

02] and all continuing applications and 

foreign counterparts (Europe, Australia 

and Canada), to Transcept 

Pharmaceuticals, Inc., which has offices 

in Pt. Richmond, CA. The patent rights 

in these inventions have been assigned 

to and/or exclusively licensed to the 

Government of the United States of 

America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to: 

A worldwide exclusive license for the use 

of scopolamine for treatment of depression, 

including major depressive disorders (MDD), 

wherein the administration of scopolamine is 

intravenous, through the buccal membrane, 

intranasal, intramuscular or through a skin 

patch. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 3, 2008, will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: David A. Lambertson, 

Ph.D., Technology Licensing Specialist, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

4632; Facsimile: (301) 402–0220; E-mail: 

lambertsond@od.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention concerns the use of 

scopolamine for the treatment of 

depression, including major depressive 

disorders (MDD). Although scopolamine 

has been employed in the treatment of 

nausea and motion sickness, the 

suitability of scopolamine for treating 

MDD was unrecognized prior to this 

invention. Current MDD treatments can 

be ineffective in large percentage of 

patients and typically do not take effect 

until 4 weeks after administration. In 

contrast, treatment with scopolamine 

has a wide-ranging and rapid effect, 

suggesting it can be effective either as a 

stand alone treatment or as a treatment 

for patients who are unresponsive to 

currently available drugs. 

A Cooperative Research and 

Development Agreement (CRADA) is 

simultaneously being negotiated to 

accompany the exclusive license 

agreement. The CRADA will involve the 

further development of the licensed 

technology between the National 

Institute of Mental Health and 

Transcept. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Applicants may also contact the 

National Institute of Mental Health 

regarding the CRADA opportunity. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: July 29, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–17817 Filed 8–1–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2008–0521] 

National Preparedness for Response 

Exercise Program 

AGENCY: Coast Guard, DHS. 

ACTION: Notice; request for public 

comment. 

SUMMARY: The Coast Guard, the Pipeline 

and Hazardous Materials Safety 

Administration, the Environmental 

Protection Agency, and the Minerals 

Management Service, in concert with 

representatives from various State 

governments, industry, environmental 

interest groups, and the general public, 

developed the National Preparedness for 

Response Exercise Program (PREP) 

Guidelines to reflect the consensus 

agreement of the entire oil spill 

response community. This notice 

announces the PREP 5-year exercise 

cycle, 2009 through 2013, and requests 

comments from the public, and requests 

volunteers from industry to participate 

in the scheduled PREP Area exercises. 

The new schedule adjustment from 3 

years to 5 years was created to align 

with the Department of Homeland 

Security’s National Exercise 5-year 

Schedule. 

DATES: Comments and related material 

must reach the Docket Management 

Facility on or before October 3, 2008. 

ADDRESSES: You may submit comments 

identified by Coast Guard docket 

number USCG–2008–0521 to the Docket 

Management Facility at the U.S. 

Department of Transportation. To avoid 

duplication, please use only one of the 

following methods: 

(1) Online: http:// 

www.regulations.gov. 

(2) Mail: Docket Management Facility 

(M–30), U.S. Department of 

Transportation, West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue, SE., Washington, DC 20590–

0001. 

(3) Hand delivery: Same as mail 

address above, between 9 a.m. and 5 

p.m., Monday through Friday, except 

Federal holidays. The telephone number 

is 202–366–9329. 

(4) Fax: 202–493–2251. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions on this notice, or 

need general information regarding the 

PREP or the 5-year exercise schedule, 

contact Lieutenant Shawn Essert, Office 

of Contingency Exercises (CG–535), U.S. 

Coast Guard, telephone 202–372–2149, 

or e-mail shawn.g.essert@uscg.mil. If 


pwalker on PROD1PC71 with NOTICES